Insider selling at this scale is notable but not alarming for a $189M biotech. Watch for any upcoming corporate events (e.g., clinical data, partnership announcements) that may have motivated the trades. The lack of 10b5-1 plan disclosure reduces the signal's reliability.
Price Chart
Executive Summary
COO/CBO Joshua Hexter and CFO Avraham Gabay collectively sold $942K in open-market shares on July 1, 2026, representing ~0.5% of Oramed's $189M market cap. The sales are moderate in size and involve two senior officers, but insider selling is a weak directional signal per academic literature, especially without evidence of 10b5-1 plans or a clear blackout context.
Key Financial Metrics
Key Facts
- Two C-suite insiders (COO/CBO and CFO) sold shares on July 1, 2026
- Total open-market sales: $942,000 at ~$4.46-$4.51 per share
- Sales represent ~0.5% of Oramed's $189M market cap
- Hexter also exercised derivatives on July 2 (non-cash events)
- Analyst consensus is bearish: 0% bullish, mostly hold/sell/strong sell ratings
Financial Impact
$942K in insider selling, about 0.5% of market cap
Risk Factors
- Additional insider selling could pressure shares
- Bearish analyst consensus may amplify negative sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORMP-1783026099934 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 13w ago | Insider Cluster | $4.60 $4.75 | ▲ +3.26% | ▼ −0.31% | $4.49 (−2.39%) |
Jun 30, 2026 13w ago | 8-K | $4.61 $4.79 | ▲ +3.90% | ▲ +1.03% | $4.49 (−2.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access